BMO Capital Markets set a $73.00 target price on Spark Therapeutics (NASDAQ:ONCE) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently commented on ONCE. UBS downgraded Spark Therapeutics from a buy rating to a neutral rating and decreased their price objective for the stock from $92.00 to $51.00 in a research note on Tuesday. SunTrust Banks set a $101.00 target price on Spark Therapeutics and gave the company a buy rating in a research note on Monday, October 16th. Leerink Swann downgraded Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 target price on the stock. in a research note on Tuesday. Evercore ISI started coverage on Spark Therapeutics in a research note on Wednesday, August 16th. They set an in-line rating and a $83.00 target price on the stock. Finally, BidaskClub raised Spark Therapeutics from a hold rating to a buy rating in a research note on Saturday, August 26th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $76.19.

Spark Therapeutics (NASDAQ ONCE) opened at $46.37 on Tuesday. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the business earned ($1.07) EPS. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts predict that Spark Therapeutics will post -7.6 EPS for the current fiscal year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the sale, the insider now owns 215,000 shares of the company’s stock, valued at approximately $15,333,800. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the completion of the sale, the director now directly owns 3,928,707 shares in the company, valued at approximately $332,486,473.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,068,809 shares of company stock worth $89,809,385. Corporate insiders own 7.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ONCE. Janus Henderson Group PLC bought a new stake in Spark Therapeutics in the 2nd quarter worth approximately $30,848,000. Orbimed Advisors LLC purchased a new position in shares of Spark Therapeutics in the 3rd quarter worth approximately $38,340,000. Jennison Associates LLC purchased a new position in shares of Spark Therapeutics in the 3rd quarter worth approximately $27,239,000. JPMorgan Chase & Co. boosted its holdings in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the period. 94.94% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Spark Therapeutics (ONCE) Given a $73.00 Price Target at BMO Capital Markets” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/spark-therapeutics-once-given-a-73-00-price-target-at-bmo-capital-markets/1767923.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.